For most of the pathogens a clinic worries about, the mental model is airborne or hand-to-hand: a cough, a droplet, an unwashed hand between patients. Candida auris does not play by that script. It is a yeast, not a virus, and it spreads mainly by touch — from a colonized patient's skin, onto the surfaces and devices around them, and then onto the next patient who meets that same bed rail, blood-pressure cuff, or ultrasound probe. It can live on those surfaces for weeks. It resists several of the disinfectants hospitals have trusted for decades. And in 2026 it is no longer a curiosity in a handful of referral hospitals — it is a steadily rising fixture of American healthcare. The uncomfortable part, for anyone who runs a clinic, is that the organism's favorite highway is the equipment we share and reprocess between patients. That is exactly the territory a sonographer, an infection preventionist, or a procurement lead already owns.

What Candida auris is — and why it broke the usual rules

Candida auris is a species of yeast first identified in 2009 and now tracked by the U.S. Centers for Disease Control and Prevention as an urgent antimicrobial-resistance threat. Three features make it different from the ordinary Candida that lives harmlessly on most of us. It is frequently resistant to antifungal drugs — sometimes to all three major classes at once — which narrows treatment to a thin margin. It colonizes skin silently, so a patient can carry it for months without a single symptom while seeding every surface they touch. And, most relevant to this article, it is unusually hard to kill in the environment: the CDC states plainly that C. auris “can survive on surfaces for a long time and not all disinfectants can kill it.”

That last sentence is the one clinics underestimate. A product that wipes out the bacteria and viruses you expect in an exam room can leave this yeast largely intact. The CDC is specific about the biggest blind spot: “Accumulating data indicate that products solely dependent on quaternary ammonia compounds (QACs) are NOT effective” against C. auris — and QAC “quats” are the workhorse active ingredient in a large share of hospital surface wipes and sprays. A clinic can be cleaning diligently, by its own written protocol, with an EPA-registered product, and still not be touching this organism.

The 2026 numbers

The growth is not subtle. In a surveillance analysis published in July 2026, the CDC reported that U.S. clinical C. auris cases climbed from 2,882 in 2022 to 4,428 in 2023 to 6,197 in 2024 — more than doubling across the two-year window. Screening cases, which catch silent colonization before it becomes an infection, rose on a parallel track, from about 6,200 in 2022 to more than 12,400 in 2024. News reporting through 2026 has tracked the organism into roughly half of U.S. states. The disease has concentrated where the most vulnerable patients are: acute-care hospitals accounted for 76.6% of clinical cases, with long-term acute-care hospitals making up most of the rest.

Mortality figures for an organism this entangled with already-sick patients are hard to attribute cleanly, but they are sobering: a 2023 CDC report found roughly a one-in-three in-hospital death rate among hospitalizations associated with the fungus. The people most at risk are not the general public. They are patients with central lines, catheters, breathing tubes, recent surgery, long ICU stays, and repeated antibiotic exposure — the exact population a hospital, a surgical center, or a specialty clinic is built to serve.

The outbreak that named the real culprit

If you want one case study that turns the abstract warning into a concrete instruction, it is the neurosciences intensive-care outbreak at Oxford University Hospitals, reported in the New England Journal of Medicine. Over roughly a year and a half, 70 patients became colonized or infected with C. auris. The hospital was not careless — it had already imposed contact isolation and enhanced, chlorine-based environmental cleaning. The outbreak kept going anyway.

When investigators dug in, the signal pointed at a single, mundane piece of shared equipment: reusable axillary (underarm) temperature probes. Case patients had been monitored with those probes far more often than controls — 86% versus 34% — and after adjusting for how sick patients were and how long they stayed, probe exposure was associated with nearly sevenfold higher odds of C. auris. Whole-genome sequencing tied the isolates recovered from the probes to the strains in the patients. The probes had been wiped between patients with quaternary-ammonium wipes, which the authors noted have poor activity against Candida. The outbreak effectively ended only when those probes were pulled from service; just a handful of cases appeared afterward.

Two lessons sit inside that story, and both are actionable for any clinic that reuses equipment. The first is that the device, not the air, was the vector — environmental air and general-surface sampling turned up the organism only rarely, but the shared probe carried it patient to patient. The second is that the wrong disinfectant is as good as no disinfectant here — the probes were being “cleaned,” on schedule, with a product that simply did not work on this yeast. A clinic reusing transducers, cuffs, glucometers, or thermometers is running the same experiment every day, and the result depends entirely on whether the chemistry and the reprocessing level actually match the organism.

What the CDC actually tells facilities to do

The guidance is less about heroics and more about closing the two gaps the Oxford outbreak exposed: the disinfectant gap and the shared-equipment gap. On the environment, the CDC directs facilities to use an EPA-registered product with a demonstrated C. auris claim — the products the EPA collects on its dedicated List P — and to clean and disinfect patient rooms at least daily and again at discharge or transfer. “No-touch” technologies like germicidal UV and vaporized hydrogen peroxide are framed as a supplement to that routine, not a replacement for it.

On equipment, the instruction is blunt: “Medical equipment that is shared between patients can spread C. auris,” so facilities should “clean and disinfect equipment after each use,” label disinfected equipment and keep it separate from dirty equipment, and assign clear responsibility for every mobile and reusable item. The CDC's own examples of the equipment at issue read like a point-of-care ultrasound cart inventory: glucometers, temperature probes, blood-pressure cuffs, ultrasound machines, nursing carts, ventilators, and physical-therapy gear.

Where SONO's world intersects this problem

Here is the honest map of where a supplier like SONO does and does not fit, because this organism punishes wishful thinking. The most important move for confirmed or suspected C. auris is a dedicated EPA List P surface disinfectant — a specific claim, verified on the label — for the room and the environmental surfaces. That is a defined category, and a clinic should source a List P product for that job and use it on the CDC's schedule.

High-level disinfection for semi-critical probes

STERIS RESERT Revital-Ox HLD — 1L

Hospital-grade hydrogen-peroxide high-level disinfectant from an authorized STERIS distributor. Pair with R60 test strips to verify the minimum recommended concentration every cycle. The validated kill step a semi-critical probe actually requires.

Shop RESERT HLD

A lower-risk routine for shared equipment

None of this requires a new committee. It is a short, written discipline that matches the reprocessing level to the device and the disinfectant to the organism. Adapt it to your equipment makers' instructions for use and your facility's policies — and, for suspected or confirmed C. auris, to your infection-prevention team's direction.

The reassuring part of an unnerving story is how specific the fix is. Candida auris is not an airborne menace that defeats ordinary precaution; it is a touch-spread organism that exploits two concrete gaps — a disinfectant that does not match it, and a shared device that never gets the reprocessing level it needs. Close those two gaps and you have taken away most of its road. Match the method to the device, verify the chemistry instead of trusting the label at a glance, keep the contact time honest, and give every shared item a clean-after-every-use owner. The schedule still moves. The difference is whether the probe in your hand is carrying the last patient's yeast to the next one.

For the everyday surface load between patients.

SONO Ultrasound Disinfecting Wipes keep carts, housings, and non-critical probe surfaces clean against the routine viral and bacterial burden — alcohol-free and gentle on equipment. For confirmed C. auris surfaces, pair them with a dedicated EPA List P product.

See Ultrasound Wipes

Related reading

• One Probe, Three Risk Levels: What the 2026 Ultrasound Infection-Control Guidance Requires
• Your RESERT Covers the Probe. What Covers the Rest of the Room? Infection Control for Pregnancy Medical Clinics
• MRSA and Back to School: The Superbug That Spikes Every Fall — and What Actually Kills It on Surfaces